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Abstract Profiling ion flux through human intracellular chloride ion channels using live-cell based 
techniques, such as patch-clamp electrophysiology, is laborious and time-consuming. The integration 
of scalable microfluidic systems with automatable protocols based on droplet-interface-bilayers (DIBs) 
within which ion channels are incorporated circumvents several limitations associated with live-cell 
measurements and facilitates testing in controllable in vitro conditions. Here, we have designed and 
tested novel microfluidic layouts for the formation of arrays of DIBs in parallel and developed the first 
example of a miniaturised, DIB-based, fluorescence assays for Cl- fluxing, allowing the investigation of 
the functional properties of the human chloride intracellular ion channel 1 (CLIC1). The microfluidic 
protocols relied on passive geometries for droplet pairing and DIB formation. Using recombinantly 
expressed CLIC1, we identified the best conditions to maximise protein integration into a lipid bilayer 
and the oligomerisation of the protein into functional ion channels. Finally, CLIC1 ion channel 
functionality was assessed relative to α-Haemolysin into microfluidic DIBs using the same Cl- fluxing 
assay. 
Keywords: microfluidics, droplet interface bilayers, chloride ion channels 
Introduction 
Ion channels are well recognised as central therapeutic targets for treating numerous 
pathophysiologies (Bagal et al. 2013). Established practise in large pharmaceutical companies 
for screening the effects of compounds on ion channels is to use automated, fluorescence-
based, high-throughput assays, to monitor changes in membrane potential or intracellular ion 
concentration at the whole cell level, or automated patch-clamp technologies that monitor 
electrophysiological readouts mostly at the cluster channel level in live cells (Bruggemann et 
al. 2006; Clare 2010). These approaches require cloning and transfection of the target protein, 
which must be abundantly expressed in the chosen cell type. For ion channels, abundant 
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expression can be problematic, as levels substantially increased above physiological conditions 
can result in altered cellular homeostasis. Due to their inner-membrane locations, intracellular 
ion channels present additional screening difficulties. 
CLIC1 is the best studied member of a family of 6 conserved proteins (CLIC1-6) in humans 
(Cromer et al. 2002). Due to their intracellular location, CLIC proteins have not been extensively 
studied. However, these proteins present an ideal model system to be studied in vitro as they 
have been shown to insert spontaneously into lipid vesicles, or artificial lipid bilayers, and form 
channels with properties similar to that seen in vivo (Tulk et al. 2000; Harrop et al. 2001). 
Recent discoveries have implied important roles for CLIC proteins in human diseases such as 
Alzheimer’s, renal dysfunction and tumorigenesis, highlighting the importance of these 
channels in critical cellular activities. 
CLIC1 proteins exist in a soluble form in the cytoplasm and undergo a large-scale structural 
rearrangement to self-insert into an inner membrane (Goodchild et al. 2011). CLIC1 insertion 
is controlled by pH, the oxidation status of the environment and the lipid composition of the 
membrane (Hossain et al. 2017). The CLIC1 monomer in the cytoplasm undergoes a 
rearrangement of the N-terminus GST-like domain to form an all-α-helical non-covalently 
bound dimer, induced under oxidising conditions (Littler et al. 2004). This structural re-
arrangement involves the formation of an intra-molecular di-sulphide bond resulting in the 
exposure of a large hydrophobic domain, which is protected in this structure between the two 
dimer subunits. Exposure of this hydrophobic surface can serve to increase the ability of CLIC1 
to dock with the membrane, as does the lower pH encountered at the membrane surface, 
which increase flexibility of the N-terminus thus promoting insertion (Goodchild et al. 2009). 
Oligomerisation and pore formation are thought to occur once CLIC1 has inserted, however 
understanding of this process is still relatively unclear.  
Droplet microfluidic technology (Theberge et al. 2010) provides miniaturised methods for 
screening ion channels, creating high-throughput assays by handling and mixing nanolitre-
picolitre amounts of drug compounds. The combination of droplet microfluidics with droplet-
interface-bilayer (DIB) protocols (Schlicht and Zagnoni 2015; Trantidou et al. 2018) offers 
potentially large-scale solutions to overcome the limitations associated with the current live 
cell-based techniques, generating artificial cell membrane structures within which ion 
channels can be studied in simplified synthetic microenvironments (Bayley et al. 2008). Of 
importance when investigating ion channel functions in microfluidic DIBs is (i) the control over 
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droplet pair matching and positioning, (ii) guaranteeing automation of the microfluidic 
protocols and (iii) achieving large data throughput (Nguyen et al. 2016; Czekalska et al. 2019). 
This approach is therefore promising for studying intracellular ion channels, complementing 
life-cell electrophysiology data in situations where ion channel location or overexpression in 
live-cell is problematic. 
Here, we present a scalable, microfluidic-DIB system for studying chloride ion channels. 
Recombinantly expressed, soluble CLIC1 was synthesized and tested off-chip to identify the 
assay conditions that maximized ion channel formation into artificial lipid bilayers. A 
miniaturised fluorescence assay based on a chloride sensitive dye indicator was developed to 
the test the functional behaviour of CLIC1 ion channels in microfluidic DIBs. This work had two 
overarching objectives: to develop a scalable microfluidic system capable of parallel DIB 
formation and simultaneous monitoring of ion flux across all DIBs via fluorescence-based 
assays; and to validate a novel multidisciplinary set of engineering and biochemistry 
methodologies for studying intracellular chloride ion channel 1 of the CLIC family. Overall, we 
show here the first example of a microfluidic DIB platform that demonstrates functionalisation 
of integrated human chloride ion channels. 
Materials and method  
Materials. List of materials, liposome and lipid preparation methods, as well as CLIC1 
preparation method, are provided in Supplementary Information (SI). 
Microfabrication and experimental setup. Microfluidic devices were fabricated in 
polydimethylsiloxane (PDMS) (Sylgard 184, Dow Corning, US) using standard soft lithography 
techniques and tested as previously described (Schlicht and Zagnoni 2015). (Details in SI). 
Off-chip insertion assay. Liposomes were suspended in 20mM HEPES, pH 7.5 or pH 5.5 and 
CLIC1 protein added in a 3.4µM:12.5mM protein:liposome ratio (v/v), and incubated overnight 
at 4 °C. Samples were ultracentrifuged at 100,000 rpm for 1 hour at 4 °C and separated into 
supernatant and pellet fractions.  Liposomes was re-suspended in 20mM HEPES, pH 7.5 or pH 
5.5 buffer and passed through a 1 ml His-Gravitrap nickel affinity column (GE Healthcare), the 
column was washed with 2 column volumes 20mM HEPES, pH 8 and the flow through 
collected. The column was washed with 10 column volumes 20mM HEPES, pH 8, followed by 
elution of any protein bound to the column with 3 column volumes of elution buffer. Samples 
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were analysed through SDS-PAGE and Western blotting using a mouse anti-CLIC antibody 
(Abcam-ab77214). 
BS3 crosslinking. 0.5mM BS3 crosslinker was added to both pellet and supernatant fractions 
and incubated at room temperature for 45 minutes.  Unreacted BS3 was quenched with 50mM 
Tris for 10 minutes at room temperature and samples analysed through SDS-PAGE and 
Western blotting. Similarly, for crosslinking of off-chip insertion assay products, 200 µL samples of 
pellet flow and elution fractions were crosslinked and analysed in the same way. 
On-chip fluorescent assay. For DIB fluxing experiments with CLIC1 (120 µg/ml), 5 mg/ml 10:1 
DOPC:cholesterol in hexadecane and alternating droplets containing non-fluorescent buffers 
(CLIC1, 10mM HEPES, 2mM H2O2, 200mM KCl, pH 5.5 - donor droplet) or fluorescent buffers 
(1.5 mg/ml SPQ, 10mM HEPES, 200mM KNO3, pH 5.5 - acceptor droplet) were used. For DIB 
fluxing experiments with ɑ-Haemolysin (2-20 µg/ml), 5 mg/ml DOPC or 4:1 DOPC:PC from 
soybean in hexadecane and alternating droplets containing non-fluorescent (10mM HEPES, 
200mM KCl, ɑ-Haemolysin, pH 7.4 - donor droplet) or fluorescent buffers (10mM HEPES, 
200mM KNO3, 1.5mg/mL SPQ, pH 7.4 - acceptor droplet) were used. 
Results 
Microfluidic architecture. A passive microfluidic design was developed to produce a ‘flip-flop 
flow’ of droplets in symmetric T-bifurcations (Fig. 1A). Two T-junctions generated two 
populations of phospholipid-stabilised, water-in-oil (W/O) droplets (one population 
encapsulating a buffer with the ion channel of interest and the other a buffer with a fluorescent 
reporter). The two trains of W/O droplets were serially arrayed in a serpentine channel leading 
to symmetric T-bifurcations (Video S1) where droplet flip-flop took place (Fig. 1A). When the 
first droplet arrived at a T-bifurcation, it randomly flowed to either the left or right channel. 
Subsequently, any other droplet followed the path of least fluidic resistance (Fig. 1B), with 
each droplet entering a new channel after the bifurcation and contributing to the change in 
resistance of the downstream channel network (Baroud et al. 2010). Interaction of 
neighbouring droplets at T-bifurcations enhanced the flip-flop sorting. Finally, after both trains 
of droplets had flown through the sorting channel network, droplet pair self-positioning (in AB 
configuration) was obtained in each droplet shift-register (Schlicht and Zagnoni 2015) (Fig. 1C) 
within which DIBs were formed (Fig. 1D). DIBs were formed within a few seconds of each other 
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and were incubated within the registers for the desired assay duration. Unwanted droplets 
were directed to a waste port (outlet1, Fig. 1A) using a manual valve. This approach provided 
high accuracy of droplet pairing and subsequent DIB formation (~97%). Therefore, the design 
was scaled up, achieving working configurations hosting 8, 16 (video S2) or 32 DIBs (Video S3) 
simultaneously.   
 
Figure 1. Microfluidic channel network designs for DIB formation. (A) Symmetric T-bifurcations were used to 
obtain a ‘flip-flop flow’ of droplets at each bifurcation, where sorting took place (B). (C) Droplets arrayed in pairs 
forming DIBs (D) within droplet shift register traps. Scale bar 200 µm. 
A second geometry based on droplet splitting in symmetric Y-bifurcations (Fig. S1 and Video 
S4 in SI) was also developed. However, this resulted in more complicated protocols, leading to 
higher accuracy of droplet pairing (~100%), but also to frequent droplet pair coalescence and 
was therefore not developed further (details in SI). 
Validation of microfluidic DIBs. Before testing CLIC1 channel functionality, a fluorescence-
based assay was developed for the characterization of Cl- ion fluxing using a chloride sensitive 
dye. This was validated in DIBs using the pore forming protein ɑ-Haemolysin (α-HL) using 
different concentrations of α-HL and of its blocker gamma cyclodextrin (γ-CD)(Gu et al. 1999). 
α-HL is a lipid bilayer spanning toxin which forms a heptameric beta-barrel structure (Kawate 
and Gouaux 2003) and is permeable to small ions, such as Na+, K+, Ca2+ and Cl- ions (Aksimentiev 
and Schulten 2005). The measurement of Cl- fluxing relied directly on the change in intensity 
of a quinoline-based Cl- fluorescent indicator, 6-methoxy-N-(3-sulfopropyl)quinolinium (SPQ). 
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SPQ is a lipid bilayer-impermeable dye that is quenched by halogen groups, such as Cl- (Fig.2A), 
thus decreasing its fluorescence intensity for increasing concentration of Cl-.  
 
Figure 2. Cl- fluxing fluorescence assay. (A) A schematic representation of SPQ Cl- fluxing through ɑ-HL pores in 
DIBs. Donor droplet (left) and acceptor droplet (right). Upon fluxing of Cl anions from the left to the right droplet, 
the intensity signal from SPQ decreased over time. (B) Brightfield image of DIBs during the assay. Scale bar is 200 
µm. C) Snapshots of the temporal evolution (from top to bottom) of the fluorescent signal in the acceptor droplet 
due to Cl- fluxing. (D) Stern-Volmer plot of Cl- fluxing with different concentrations of α-HL. (E) Stern-Volmer plot 
of Cl- fluxing for different concentrations of γ-CD and a fixed concentration of α-HL. Black lines are a linear square 
fit of the experimental points for each protein or blocker concentration. 
Arrays of droplets in acceptor-donor pairs were formed within each droplet shift register trap, 
with one droplet encapsulating α-HL in a Cl- buffer and its neighbour containing SPQ in an 
isosmotic Cl- free buffer (Fig. 2A). The change in fluorescent intensity was monitored 
immediately after DIB formation for 10-60 minutes. α-HL monomers are known to oligomerise 
into a heptamer on the membrane surface, then spontaneously insert into the bilayer, forming 
ion channel pores (15-45 Å diameter) within DIBs. This allowed fluxing of Cl- ions, but not SPQ 
molecules, quenching the dye over time (Fig. 2C-E). As a control, the same experiment was 
performed with donor droplets not containing α-HL, showing no detectable decrease in 
fluorescence (not shown).  The Stern-Volmer relationship was used to estimate the quenching 
rate for varying concentrations of Cl- (Illsley and Verkman 1987) (Fig. S2A in SI). Increasing 
concentrations of α-HL (2, 4, 8 and 16 µg/ml) produced faster fluxing of Cl-, likely due to the 
greater number of α-HL pores being formed (Fig. 2D) in a DIB. γ-CD, a cyclic oligosaccharide 
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that reversibly binds to functional α-HL pores and transiently obstructs the ion channel pore, 
was used at different concentrations to reduce the Cl- fluxing through α-HL (16 µg/mL) ion 
channels. As expected (Fig. 2E), higher concentrations of the blocker progressively decreased 
the rate of fluxing of Cl- across α-HL pores in the DIBs. 
Off-chip characterization of CLIC1 insertion into lipid bilayers.  Metamorphic CLIC1 has been 
shown to form an all-α-helical non-covalently bound dimer under oxidising conditions (Littler et al. 
2004), while lower pH has been shown to influence the stability of CLIC1, destabilising the N-terminus 
and exposure of the hydrophobic region, which in turn primes it for insertion to the membrane 
(Goodchild et al. 2009). To understand the oligomerisation mechanisms of CLIC1 upon insertion into 
the membrane, we incubated CLIC1 with liposomes at both pH 7.5 and pH 5.5 under both oxidising (2 
mM H2O2) and reducing conditions (2 mM DTT). Ultracentrifugation was used to separate liposomes 
and bound protein into the pellet fraction, whilst any free protein remained in the supernatant 
fraction. BS3 crosslinker was added to determine the oligomerisation of CLIC1 by covalently linking 
monomers, thus enabling visualisation on SDS-PAGE. In reduced conditions, CLIC1 remained as a 
monomer at both pH 7.5 and pH 5.5 in the absence of liposomes (Fig. 3A&B; Lane 10) and in the 
presence of liposomes in both the pellet and supernatant fractions (Fig. 3A&B; Lanes 11&12). 
However, in oxidising conditions at pH 7.5 CLIC1 existed as both monomers and dimers in the complete 
absence of liposomes (Fig. 3A; Lane 4) and also when bound to liposomes (Fig. 3A; Lane 5). but 
interestingly not in the supernatant, which, whilst also containing free CLIC1, only contained 
monomers (Fig. 3A; Lane 6). This indicates that it is only under oxidising conditions at pH 5.5 that CLIC1 
exists in higher oligomeric structures, both free in solution (Fig. 3B; Lane 4) and bound to liposomes 
(Fig. 3B; Lane 5) where, as well as the presence of CLIC1 monomer, there are also bands corresponding 
to the presence of dimer, trimer, tetramer and other higher order structures. In the supernatant 




Figure 3. CLIC1 oligomerisation analysed by BS3 crosslinking.  Western blot analysis of BS3 crosslinking 
experiments at (A) pH 7.5 and (B) pH 5.5 under oxidising (2 mM H2O2) and reducing (2mM DTT) conditions, 
detected by anti-CLIC1 antibodies. Pellet (P) - liposomes and bound protein, and supernatant (S) - free protein 
fractions. The CLIC1 monomer is ~30 kDa. (*) indicates dimer formation. 
To further test CLIC1 insertion, we developed a purification technique to isolate only liposomes 
containing inserted CLIC1 protein. When incubated with liposomes, the CLIC1 protein will insert 
with the N-terminus contained with the interior of the liposome and the C-terminus remaining 
exposed (Fig. 4A) (Tonini et al. 2000). The His-tag located at the N-terminus of the CLIC1 
construct would be protected within the liposome.   
Following ultracentrifugation, insertion of CLIC1 into DOPC liposomes was confirmed by 
applying the resulting fractions to His-Gravitrap nickel affinity columns. If CLIC1 was inserted 
into the liposomes, the His-tag will be located within the liposome and the protein and 
liposomes will pass through the column, collected in the initial ‘flow-through sample’. Instead, 
if the latter is bound to the outside of the liposome or free in solution, it will bind to the column 
and only be released by addition of elution buffer, collected in the ‘elution sample’ (Fig. 4B). 
Results were visualised by SDS-PAGE and Western blotting (Fig. 4C). CLIC1 was only present in 
the flow-through sample in the pellet fraction under oxidising conditions at both pH 7.5 and 
pH 5.5, indication that CLIC1 is inserted in the liposome and therefore able to pass through the 
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column (Fig. 4C; Lanes 1&9). CLIC1 was also eluted from the nickel-column in the pellet fraction 
at both pH 7.5 and 5.5 (Fig. 4C; Lanes 2&10), suggesting that not all the CLIC1 is inserted to the 
membrane and some is associated to the outside of the liposome. At pH 7.5, there was also 
some CLIC1 in the elution fraction of the oxidised supernatant (Fig. 4C; Lane 4), whilst at pH 
5.5 there was no detectable CLIC1 in the supernatant fraction in either the flow-through or 
elution (Fig. 4C; Lanes 11&12). Under oxidising conditions, the total level of insertion for pH 
7.5 was calculated to be 11.5%, whilst pH 5.5 was 41.2% (Fig. 4C). 
 
Figure 4. Analysis of CLIC1 insertion into DOPC liposomes.  (A) Schematic of CLIC1 inserted in a liposome. The N-
terminus containing the His-tag is protected inside the liposome with the C-terminus exposed. (B) Schematic of 
the nickel column experiments to test CLIC1 insertion into liposomes. (C) Western blot analysis of nickel column 
experiments at pH 7.5 under oxidising (2mM H2O2) and reducing (2mM DTT) conditions, and pH 5.5 under 
oxidising (2mM H2O2) and reducing (2 mM DTT) conditions, detected by anti-CLIC1 antibody. (D) BS3 crosslinking 
analysis of the Pellet Flow and Elution fractions under oxidising conditions (2mM H2O2) at pH 5.5 in comparison 
to CLIC1 protein free in solution in the absence of liposomes. (*) indicate oligomer formation. (E) % CLIC1 in each 
oligomeric state was calculated as a percentage of [Individual oligomeric state /Total protein for sample] with 
each value adjusted for background. 
In reduced conditions, CLIC1 was only found in the elution samples at both pH 7.5 and 5.5 in 
both the pellet and supernatant fractions, indicating that CLIC1 was not inserted and was only 
associated with the liposome in the pellet (Fig. 4C; Lanes 6&14) or free in solution in the 
supernatant (Fig. 4C; Lane 8&16). 
10 
 
Following this, the flow and elution samples at pH 5.5 under oxidising conditions were treated with 
BS3 to determine the oligomerisation of CLIC1 inserted into liposomes (flow) and estimate the amount 
of CLIC1 bound to the outside of liposomes (elution).  A lower proportion of CLIC1 inserted into the 
liposomes as a monomer, instead it predominantly existed as a dimer and other higher order 
oligomeric structures (Figure 4D; Lane 2). However, CLIC1 that was bound to the outside of the 
liposome predominantly existed as a monomer, with only a small proportion present as a dimer, with 
no evidence of any other higher order structures (Figure 4D; Lane 3). These experiments were 
repeated in triplicates (Fig. 4E) and image analysis showed that just under 60% of CLIC1 was present 
as a monomer in the absence of liposomes, with this figure reduced to just under 30% for CLIC1 
inserted into liposomes and over 80% of CLIC1 bound to the outside of liposomes as a monomer. On 
average, over 35% of CLIC1 inserted into liposomes was present as a dimer, with approximately 15% 
of each existing as trimers and tetramers. Whereas, on average, approximately 15% existed as CLIC1 
dimers bound to the outside of the liposomes with no other higher order structures detected. 
Investigating functional pore formation of CLIC1. Having identified favourable conditions for 
CLIC1 insertion into lipid bilayers and characterised its oligomeric structures in liposomes, 
CLIC1 was tested in microfluidic DIBs to study the formation of functional CLIC1 chloride ion 
channels. Arrays of droplets in acceptor-donor pairs were formed within droplet shift-
registers, with the donor droplet containing CLIC1 proteins. The change in fluorescent intensity 
was monitored immediately after DIB formation and recording was performed for at least ~90 
minutes (Fig. 5). In the case of a functional CLIC1 pore, the fluorescent signal from the acceptor 
droplet decreased over time, with variable rate and duration. With respect to α-HL 
experiments where fluxing was observed in all experiments, CLIC1 yielded a success rate of 
~5%, reflecting the outcome of the off-chip insertion experiments (15% of CLIC forming 
tetramers, most likely to be the functional form). This corresponds to approximately 5% of the 




Figure 5. CLIC1 ion channel fluxing in DIBs. (A) Schematic shows functional CLIC1 assembly into a lipid bilayer 
and consequent Cl- fluxing. (B) Representative traces of fluorescent intensity from acceptor droplets (containing 
SPQ dye) in DIBs over 90 min acquisition period. Trace x shows sustained fluorescence signal in the case of no 
CLIC1 ion channel. Trace y shows decrease in fluorescence intensity due to a functional CLIC1 ion channels and 
Cl- fluxing across a DIB. (C) Representative traces of two Cl- fluxing behaviours in CLIC1 ion channels. (D) Difference 
between the two Cl- fluxing behaviours in (C). Data shown as average value with standard errors.  
When testing CLIC1 functionality, the fluorescence intensity of the acceptor droplets was 
quenched at smaller rates than when using α-HL. Two distinct quenching behaviours (Fig. 
5C&D) were identified in the Stern-Volmer plots of Cl- fluxing: either an almost constant 
quenching rate (ɑ in Fig. 5C(i)) or two almost constant quenching rates (β and γ in Fig. 5C(ii)), 
suggesting that either an increasing number of pores or different oligomeric states of the CLIC1 
ion channel were present in the DIBs over time, consistently with previous reports using 
electrophysiology in live cells and planar lipid bilayers for CLIC1 (Warton et al. 2002, Costa et 
al. 2013).  
Discussion 
The proposed microfluidic architecture offers several advantages compared to others based 
on serial (Schlicht and Zagnoni 2015; Nguyen et al. 2016) or parallel (Czekalska et al. 2019) DIBs 
designs. These are: its scalability, the way DIBs can be formed within a few seconds of each 
other and the robustness of achieving droplet pairing in AB configuration and in parallel 
fashion. The parallel formation of DIBs is a particular advantage with respect to a serial 
architecture where, for increasing numbers of DIBs, a linearly increasing time lag is present 
between the first and the last DIB being formed, which impacts negatively when upscaling the 
platform. Importantly, the proposed architecture is free from droplet synchronisation strategies 
relying either on laborious tuning of droplet flows (Schlicht and Zagnoni 2015) or sophisticated 
geometries (Hong et al. 2010; Ahn et al. 2011; Xu et al. 2012; Gupta et al. 2011). With respect to these 
previous reports (stating 70% accuracy) (Bai et al. 2010), our approach produced better pairing 
efficiency (~97%) and the potential for more complex assays based on droplet packing 
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combinations (Fig. S3 in SI). Ultimately, larger versions of the proposed platform could offer a 
greater number of experiments carried out in parallel. With respect to electrophysiological 
measurement, this platform has potential to offer a cost-effective approach with greater 
throughput of information in exchange for poorer time resolution in ion channel response, 
thus complementing electrophysiology experiments. Therefore, this approach could be used 
in drug discovery for pre-screening large libraries of compounds, performing mechanistic 
studies and identifying hits, prior to more detailed electrophysiology measurements.  







𝟐𝑵 ∙ 𝑺 ∙ 𝑫 ∙ 𝒌𝒗𝒔
𝑽 ∙ 𝑳
𝒕 + 𝟏 
where N is the number of functional pores inserted into a DIB; S is the cross-section area of a 
pore; D is diffusion coefficient of the medium; Co is the original concentration in the donor 
droplet; L is the length of the pore; Va is the volume of the acceptor droplet. Considering 
negligible droplet shrinkage over the duration of the assay, D, Co, Kvs, V, and L are constant 
throughout the experiment. The only parameters influencing the fluorescence quenching rate 
are N and S. For α-HL experiments, at each protein concentration (Fig. 2D), the rate of change 
of Fo/F(t) over time was approximately constant, suggesting that the number of functional α-
HL pores inserted into a lipid bilayer did not change over the course of the measurements. 
Whereas, for a fixed α-HL concentration, different γ-CD blocker concentrations affected the 
rate at which the section of the pore was blocked (Fig. 2E). 
Results from the off-chip CLIC1 insertion assays indicate that CLIC1 only oligomerises to 
potential channel forming structures (trimers, tetramers and higher) under oxidising 
conditions at pH 5.5 (Fig. 3), confirming that low pH is essential for ion channel formation. The 
redox conditions also strongly influenced the efficiency of CLIC1 insertion into liposomes. Of 
the total CLIC1 that inserted into the liposome at pH 5.5 under oxidising conditions, the 
majority oligomerised (70%) (Fig. 4E), consistently with previous reports (Littler et al. 2004). 
Interestingly, despite having mixed monomers and oligomers under oxidising conditions in the 
absence of liposomes, in the presence of liposomes any CLIC1 that oligomerises becomes 
membrane bound. Essentially, this indicates that any CLIC1 undergoing the change to all- α-
helical structure is able to insert into the membrane and oligomerise. Ultimately, these results 
account for the low insertion rates observed in the on-chip assays (Fig. 4E). 
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The latter result highlights the limitation of platforms based on lipid-bilayer harbouring ion 
channels, where channel insertion and its functional status is independent from the platform. 
This is a common issue in the literature, which limits many studies to the investigation of 
bacterial, spontaneously inserting ion channels. Our automated and simplified microfluidic 
approach facilitates the increase of data throughput in cases where low functional ion channel 
insertion is present.  
Differences in flux rates are apparent between the CLIC1 experiments and those for α-HL. 
Firstly, α-HL will only integrate upon oligomerisation, therefore any membrane located protein 
will be found in a pore, whereas CLIC1 will integrate and then oligomerise to form a channel, 
resulting in multiple non-active membrane species. In addition, the α-HL pore is between 15 
and 45 Å, whereas the CLIC1 channel is proposed to be between 1 and 5 Å. Furthermore, while 
the number of α-HL pores remained approximately constant for the duration of experiments, 
when testing CLIC1 two behaviours occurred. One where the pore size and number of pores 
remained approximately constant and one where a lower fluxing rate was observed prior to a 
higher one (Fig. 5 C&D). In our assay, when observing a change in fluxing rate, it is not possible 
to distinguish whether this was caused by an increase in the number of ion channels in the DIB 
or an increase in their pore size. Our results (Fig. 5D) suggest that, potentially, a higher 
oligomeric structure of the CLIC1 pore is obtained over time, reflecting the different levels of 
oligomeric structures observed in the off-chip assays (Fig. 4E). This finding compares well with 
previous electrophysiology reports of CLIC1 ion channels having a ‘slow conductance slow 
kinetics’ and ‘high conductance fast kinetics’ gating (Warton et al. 2002, Costa et al. 2013). 
Conclusions 
We have shown a novel microfluidic architecture, designed to simplify the automation of 
droplet-based operations, to precisely form DIBs and to assess the functionality of a membrane 
integrated ion channel, CLIC1. The performance of the microfluidic system for studying DIB 
processes was characterised and a novel fluorescence-based assay for studying Cl- fluxing was 
developed together with a simplified analytical model of fluxing. The proposed paradigm, 
combining biochemistry procedures and scalable microfluidic assays, has the potential for 
creating powerful and efficient tools for cell-free drug screening of integrated membrane 
proteins, offering a cost-effective approach to analyse the function of intracellular ion channels 
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